Abstract

Background: Previous studies show that mTOR inhibitors decrease the risk of cancer development after kidney transplantation. However, the effect of cumulative doses of mTOR inhibitors on cancer after kidney transplantation is not well known. Methods: In the current study, patients were registered into a national database in Taiwan. Between year 2000 and 2013, 4,563 patients received kidney transplantation. They were divided into two groups, according to mTOR inhibitors usage. The cumulative dose of mTOR inhibitors was recorded. Patients were followed-up until de novo cancer development, death, or the end of 2014. Results: Patients were divided into two groups: mTOR inhibitors users (study group, n = 828) and mTOR inhibitors non-users (control group, n = 3,735). The median follow-up duration was 7.8 years. The risk of de novo cancer (hazards ratio (HR) 0.80, 95% CI [0.60-1.09], p = 0.16) and risk of death (HR 1.14, 95% CI [0.82-1.60], p = 0.43) was not different between mTOR inhibitor user and non-user groups. Neither high- nor low-dose exposure to mTOR inhibitors was associated with increased risk of cancer or mortality. Analysis of cancer subtypes showed no influence by mTOR inhibitors. In addition, the cause of mortality was not significantly different between the two groups. Discussion: We could not find the association of mTOR inhibitors use and risk of de novo cancer development or mortality in patients with kidney transplantation in Chinese patients. Cumulative exposure to mTOR inhibitors did not change the results.

Original languageEnglish
Article numbere5864
JournalPeerJ
Volume2018
Issue number11
DOIs
Publication statusPublished - Jan 1 2018

Fingerprint

kidney transplant
Kidney Transplantation
neoplasms
Neoplasms
Hazards
Mortality
dosage
cumulative exposure
death
Kidney Neoplasms
Taiwan
Databases
Control Groups
duration

Keywords

  • Cancer
  • Chronic kidney disease
  • Kidney transplantation
  • Mortality
  • MTOR inhibitors

ASJC Scopus subject areas

  • Neuroscience(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)

Cite this

Cancer and mTOR inhibitors in kidney transplantation recipients. / Kao, Chih Chin; Liu, Jia Sin; Chang, Yu Kang; Lin, Ming Huang; Lin, Yen Chung; Chen, Hsi Hsien; Chang, Wei Chiao; Hsu, Chih Cheng; Wu, Mai Szu.

In: PeerJ, Vol. 2018, No. 11, e5864, 01.01.2018.

Research output: Contribution to journalArticle

Kao, Chih Chin ; Liu, Jia Sin ; Chang, Yu Kang ; Lin, Ming Huang ; Lin, Yen Chung ; Chen, Hsi Hsien ; Chang, Wei Chiao ; Hsu, Chih Cheng ; Wu, Mai Szu. / Cancer and mTOR inhibitors in kidney transplantation recipients. In: PeerJ. 2018 ; Vol. 2018, No. 11.
@article{86c4ab68753746a18e62a65e7075fea6,
title = "Cancer and mTOR inhibitors in kidney transplantation recipients",
abstract = "Background: Previous studies show that mTOR inhibitors decrease the risk of cancer development after kidney transplantation. However, the effect of cumulative doses of mTOR inhibitors on cancer after kidney transplantation is not well known. Methods: In the current study, patients were registered into a national database in Taiwan. Between year 2000 and 2013, 4,563 patients received kidney transplantation. They were divided into two groups, according to mTOR inhibitors usage. The cumulative dose of mTOR inhibitors was recorded. Patients were followed-up until de novo cancer development, death, or the end of 2014. Results: Patients were divided into two groups: mTOR inhibitors users (study group, n = 828) and mTOR inhibitors non-users (control group, n = 3,735). The median follow-up duration was 7.8 years. The risk of de novo cancer (hazards ratio (HR) 0.80, 95{\%} CI [0.60-1.09], p = 0.16) and risk of death (HR 1.14, 95{\%} CI [0.82-1.60], p = 0.43) was not different between mTOR inhibitor user and non-user groups. Neither high- nor low-dose exposure to mTOR inhibitors was associated with increased risk of cancer or mortality. Analysis of cancer subtypes showed no influence by mTOR inhibitors. In addition, the cause of mortality was not significantly different between the two groups. Discussion: We could not find the association of mTOR inhibitors use and risk of de novo cancer development or mortality in patients with kidney transplantation in Chinese patients. Cumulative exposure to mTOR inhibitors did not change the results.",
keywords = "Cancer, Chronic kidney disease, Kidney transplantation, Mortality, MTOR inhibitors",
author = "Kao, {Chih Chin} and Liu, {Jia Sin} and Chang, {Yu Kang} and Lin, {Ming Huang} and Lin, {Yen Chung} and Chen, {Hsi Hsien} and Chang, {Wei Chiao} and Hsu, {Chih Cheng} and Wu, {Mai Szu}",
year = "2018",
month = "1",
day = "1",
doi = "10.7717/peerj.5864",
language = "English",
volume = "2018",
journal = "PeerJ",
issn = "2167-8359",
publisher = "PeerJ Inc.",
number = "11",

}

TY - JOUR

T1 - Cancer and mTOR inhibitors in kidney transplantation recipients

AU - Kao, Chih Chin

AU - Liu, Jia Sin

AU - Chang, Yu Kang

AU - Lin, Ming Huang

AU - Lin, Yen Chung

AU - Chen, Hsi Hsien

AU - Chang, Wei Chiao

AU - Hsu, Chih Cheng

AU - Wu, Mai Szu

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Background: Previous studies show that mTOR inhibitors decrease the risk of cancer development after kidney transplantation. However, the effect of cumulative doses of mTOR inhibitors on cancer after kidney transplantation is not well known. Methods: In the current study, patients were registered into a national database in Taiwan. Between year 2000 and 2013, 4,563 patients received kidney transplantation. They were divided into two groups, according to mTOR inhibitors usage. The cumulative dose of mTOR inhibitors was recorded. Patients were followed-up until de novo cancer development, death, or the end of 2014. Results: Patients were divided into two groups: mTOR inhibitors users (study group, n = 828) and mTOR inhibitors non-users (control group, n = 3,735). The median follow-up duration was 7.8 years. The risk of de novo cancer (hazards ratio (HR) 0.80, 95% CI [0.60-1.09], p = 0.16) and risk of death (HR 1.14, 95% CI [0.82-1.60], p = 0.43) was not different between mTOR inhibitor user and non-user groups. Neither high- nor low-dose exposure to mTOR inhibitors was associated with increased risk of cancer or mortality. Analysis of cancer subtypes showed no influence by mTOR inhibitors. In addition, the cause of mortality was not significantly different between the two groups. Discussion: We could not find the association of mTOR inhibitors use and risk of de novo cancer development or mortality in patients with kidney transplantation in Chinese patients. Cumulative exposure to mTOR inhibitors did not change the results.

AB - Background: Previous studies show that mTOR inhibitors decrease the risk of cancer development after kidney transplantation. However, the effect of cumulative doses of mTOR inhibitors on cancer after kidney transplantation is not well known. Methods: In the current study, patients were registered into a national database in Taiwan. Between year 2000 and 2013, 4,563 patients received kidney transplantation. They were divided into two groups, according to mTOR inhibitors usage. The cumulative dose of mTOR inhibitors was recorded. Patients were followed-up until de novo cancer development, death, or the end of 2014. Results: Patients were divided into two groups: mTOR inhibitors users (study group, n = 828) and mTOR inhibitors non-users (control group, n = 3,735). The median follow-up duration was 7.8 years. The risk of de novo cancer (hazards ratio (HR) 0.80, 95% CI [0.60-1.09], p = 0.16) and risk of death (HR 1.14, 95% CI [0.82-1.60], p = 0.43) was not different between mTOR inhibitor user and non-user groups. Neither high- nor low-dose exposure to mTOR inhibitors was associated with increased risk of cancer or mortality. Analysis of cancer subtypes showed no influence by mTOR inhibitors. In addition, the cause of mortality was not significantly different between the two groups. Discussion: We could not find the association of mTOR inhibitors use and risk of de novo cancer development or mortality in patients with kidney transplantation in Chinese patients. Cumulative exposure to mTOR inhibitors did not change the results.

KW - Cancer

KW - Chronic kidney disease

KW - Kidney transplantation

KW - Mortality

KW - MTOR inhibitors

UR - http://www.scopus.com/inward/record.url?scp=85056333289&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85056333289&partnerID=8YFLogxK

U2 - 10.7717/peerj.5864

DO - 10.7717/peerj.5864

M3 - Article

VL - 2018

JO - PeerJ

JF - PeerJ

SN - 2167-8359

IS - 11

M1 - e5864

ER -